Nasal septum perforation is a rare complication that can occur
due to certain antineoplastic agents, especially antiangiogenic
agents such as bevacizumab. There has been no case of nasal
perforation case due to the treatment of lapatinib+capecitabine
so far. Our case is nasal septum perforation occuring with the
38-year-old patient diagnosed with premenopausal advanced
breast cancer during the treatment of lapatinib+capecitabine.
It occured as epistaxis in the 30th month of patients treatment.
In the anterior rhinoscopy, nasal septum perforation
was diagnosed. The patient had no nasal irritant or cocaine,
or no trauma story. Although it is a rare complication, perforation
due to lapatinib+capecitabine should be considered
in the advanced breast cancer patients with the treatment of
lapatinib+capecitabine when nasal symptoms (epistaxis, nasal
congestion, local pain, irritation, rhinorrhea) occur.
Keywords: Capecitabine; lapatinib; nasal septum perforation
